ID

23348

Description

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Mots-clés

Versions (1)
  1. 02/07/2017 02/07/2017 -
Détendeur de droits

Genentech, Inc.

Téléchargé le

2 juillet 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

TREATMENT CROSSOVER (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330

Anglais

TREATMENT CROSSOVER (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330

1 Formulaires  
Patient administration
Description

Patient administration

Subject Number
Description

PT

Type de données

integer

Alias
UMLS CUI [1]
C2348585
Subject Initials:
Description

PTINIT

Type de données

text

Alias
UMLS CUI [1,1]
C1997894
UMLS CUI [1,2]
C2986440
Report Date:
Description

VDT

Type de données

date

Alias
UMLS CUI [1,1]
C1302584
TREATMENT CROSSOVER (UNSCHEDULED)
Description

TREATMENT CROSSOVER (UNSCHEDULED)

Did the subject participate in the treatment crossover plan?
Description

CROSSOVER_PARTICIPAT [CRSRPAR]

Type de données

boolean

Alias
UMLS CUI [1]
C0150097
Indicate the visit month at which the subject’s treatment crossover was implemented:
Description

If Yes:

Type de données

integer

Were both early crossover criteria listed below met?
Description

If the crossover visit month was prior to the Month 25 visit, complete the following: • Has lost >=10 letters on EDTRS BCVA from Baseline due to DME, as confirmed on >= 2 consecutive scheduled study visits, and • OCT images confirm persistent edema (CFT 250 μm) at the same visits.

Type de données

boolean

Alias
UMLS CUI [1]
C0242801
Indicate the reason why the subject did not participate in the treatment crossover:
Description

If No:

Type de données

integer

Alias
UMLS CUI [1]
C0680251
Other (specify):
Description

REASON_TREAT_CRSOVR [NCRSVR]

Type de données

text

Alias
UMLS CUI [1]
C0680251
Retour au début de la page

Similar models

TREATMENT CROSSOVER (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Patient administration
PT
Item
Subject Number
integer
C2348585 (UMLS CUI [1])
PTINIT
Item
Subject Initials:
text
C1997894 (UMLS CUI [1,1])
C2986440 (UMLS CUI [1,2])
VDT
Item
Report Date:
date
C1302584 (UMLS CUI [1,1])
Item Group
TREATMENT CROSSOVER (UNSCHEDULED)
CROSSOVER_PARTICIPAT [CRSRPAR]
Item
Did the subject participate in the treatment crossover plan?
boolean
C0150097 (UMLS CUI [1])
TRT_CRSOVR_IMP_MTH [RXCOMO]
Item
Indicate the visit month at which the subject’s treatment crossover was implemented:
integer
ELIGIBILITY_CRITERIA [ELIGCR]
Item
Were both early crossover criteria listed below met?
boolean
C0242801 (UMLS CUI [1])
Item
Indicate the reason why the subject did not participate in the treatment crossover:
integer
C0680251 (UMLS CUI [1])
REASON_TREAT_CRSOVR [NCRSVR]
Code List
Indicate the reason why the subject did not participate in the treatment crossover:
CL Item
Subject has discontinued study treatment (1)
CL Item
Subject refused to participate in the treatment crossover plan (2)
CL Item
Other (specify): (3)
REASON_TREAT_CRSOVR [NCRSVR]
Item
Other (specify):
text
C0680251 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial